Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard

Executive Summary

After an almost two-year hiatus from strict adherence to the review timeframes set forth in the Prescription Drugs User Fee Act, Office of New Drugs Director John Jenkins has told the drug review staff that, once again, they should strive to meet the user fee deadlines

You may also be interested in...



'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Implementer of many drug review changes will leave in January after nearly 32 years of public service.

Orphan Designation Requests To Get Slower Reviews

FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.

Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining

HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.

Related Content

Topics

UsernamePublicRestriction

Register

PS051749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel